Navigation Links
Spectros Corp. Enters Into Optical Biotechnology Patent Sale Agreement With Philips Electronics N.V.
Date:5/3/2010

PORTOLA VALLEY, Calif., May 3 /PRNewswire/ -- Spectros announced today that it entered into a patent sale agreement with Koninklijke Philips Electronics N.V. ( PHG). Under this agreement, Philips purchased a patent related to technology for multispectral pulse oximetry, an approach first developed and patented by Spectros.

"We are pleased that Philips has recognized the value inherent in Spectros' intellectual property covering multispectral pulse oximetry," noted David Benaron, CEO. "Spectros has one of the largest optical biotechnology portfolios in the medical, sensing, and illumination markets."

Previously, Spectros has closed technology sale, license, or access agreements, including with LI-COR, Caliper Life Sciences, FirstScan, Merck Research, Rita Medical, and Boston Scientific Corporation.

About Spectros

Spectros markets advanced molecular sensing and imaging devices that shed light on ischemia and cancer. The company's champion product, the T-Stat VLS Tissue Oximeter, is the first medical device FDA-approved as sensitive to ischemia, an insufficient supply of oxygen to tissue. T-Stat is the only commercially-available tissue oximeter that utilizes state-of-the-art white LEDs and broadband visible light spectroscopy (VLS) technology. The non-invasive T-Stat system is used clinically to provide an absolute, continuous, and real-time tissue oxygenation value, utilizing 260 wavelengths versus only 2-4 wavelengths for competing NIRS products. The Spectros T-Stat competes in the ICU oximetry marketplace with noninvasive devices from Somanetics, CAS Medical, and Masimo Corporation; and competes in the Plastic Surgery market with Vioptix.

Spectros is also developing Continuum and ProstaFluor molecular diagnostic tools for breast and prostate cancer, currently in phase I/II human clinical trials supported by the National Cancer Institute. Spectros is a venture-supported private concern and markets its products in the U.S. and internationally.

(Note: Forward-looking statements are intended as a guide only, and do not constitute an offer for investment nor a guarantee of future events or returns. Certain Spectros applications described above have not been reviewed and approved by the FDA, and are therefore labeled for investigational use only. T-Stat, FireFly, Continuum, VLS, and ProstaFluor are trademarks of Spectros).

SPECTROS CONTACT: For further information, visit www.spectros.com, or contact Ms. Elizabeth van Thillo at info@spectros.com or at (650) 529-2865.


'/>"/>
SOURCE Spectros
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Bioimpedance Spectroscopy is More Accurate and Reliable Than Other Methods of Subclinical Assessment of Lymphedema in Breast Cancer Patients, According to Paper Published in Journal of Clinical Oncology
2. FDA Grants Market Clearance for the LipiScan(TM) Coronary Imaging System Developed by InfraReDx, Inc. - A Novel Spectroscopy System for the Identification of Lipid Core Containing Plaques of Interest in the Coronary Arteries
3. BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2009 Financial Results
4. BioSpecifics Technologies Corp. Announces Availability of XIAFLEX(TM) for the Treatment of Dupuytrens Contracture
5. BioSpecifics Technologies Corp. to Host Conference Call to Report Fourth Quarter and Full Year 2009 Financial Results on March 10, 2010
6. Cantel Medical Corp. To Hold Conference Call To Discuss Results For Its Second Quarter Ended January 31, 2010
7. Corgenix Medical Corp. Announces Launch of Products for Automated Systems
8. BioSpecifics Technologies Corp. to Present at Cowen and Company 30th Annual Health Care Conference
9. BioSpecifics Technologies Corp. Announces FDA Approval of XIAFLEX(TM) for Treatment of Dupuytrens Contracture
10. World Heart Corp. Completes $7.3 Million Private Placement
11. ETEX Corporation Announces Distribution Agreement With OrthoPediatrics Corp.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... Research and Markets has announced the addition of the ... to 2021" report to their offering. ... , , The immunohistochemistry (IHC) ... a CAGR of 7.3% during the forecast period of 2016 to 2021. ... rapidly increasing geriatric population across the globe are the primary driving the ...
(Date:12/7/2016)... 7, 2016  Palatin Technologies, Inc. ("Palatin") (NYSE ... a previously disclosed underwritten public offering of units ... as sole book-running manager, Roth Capital Partners acted ... as co-manager for the offering. "This ... net proceeds, allowing us to continue advancing bremelanotide ...
(Date:12/7/2016)... , Dec. 7, 2016 DelveInsight,s, ... report provides in depth insights on the ... the Janus Kinase 3 (JAK3) Inhibitors. The ... various stages of development including Discovery, Pre-clinical, ... and Preregistration. Report covers the product clinical ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... December 07, 2016 , ... When it came time to blow out his candles on ... later, the Pediatric Heart Transplant team at Joe DiMaggio Children’s Hospital surprised his ... the hospital’s 30th heart transplant recipient. , “He was playing at home, when we ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... financial consultation services to residents in the Sacramento/Folsom region, is initiating a charity ... facility. , The Another Choice Another Chance treatment center in Sacramento works to ...
(Date:12/7/2016)... , ... December 07, 2016 , ... AlignLife clinics nationwide ... Many children are not fortunate enough to receive bountiful gifts wrapped tightly under a ... can bring to the children of the world. , In exchange for generous donations, ...
(Date:12/7/2016)... OR (PRWEB) , ... December 07, 2016 , ... Sharon ... Water, Global Climate Change and Your Health on Voice of America, declared on her ... to call attention to the fact that when these bullies attack leaders in corporate ...
(Date:12/7/2016)... ... December 07, 2016 , ... Delete® - Tattoo Removal and Laser Salon Offers ... Season. Save Up To 33% Off Botox® and Juvederm® Products Now Through December 31, ... with Delightful Deals on Botox® and Juvederm® just in time for the ...
Breaking Medicine News(10 mins):